Core Insights - The U.S. box office has seen a significant increase of over 25% compared to the same period last year, contributing to Marcus Theatres achieving its second-best pre-Christmas weekend since 2021 [1][2]. Company Performance - Marcus Theatres is experiencing a successful holiday season, driven by the release of highly anticipated films such as Avatar: Fire and Ash, which is expected to attract audiences throughout the holiday season and into 2026 [3]. - The company has recorded a record Memorial Day weekend earlier this year and continues to offer a diverse slate of films that appeal to various demographics [2]. Upcoming Releases and Events - Christmas Day is projected to be one of the busiest moviegoing days, with new films like Anaconda, Marty Supreme, and Song Sung Blue set to debut on December 25 [5]. - Marcus Theatres will also screen the finale of the popular TV show Stranger Things at select locations on December 31 and January 1 [6]. Promotions and Collectibles - The company is offering limited-time collectibles and giveaways, including Anaconda collectible prints and special popcorn buckets, as well as scratch-off cards for moviegoers with various prizes [8]. Company Overview - Marcus Theatres operates 985 screens across 78 locations in 17 states, making it the fourth-largest theatre circuit in the United States [9]. - The parent company, Marcus Corporation, is a leader in the lodging and entertainment industries, managing 16 hotels and resorts in addition to its theatre operations [10].

MONTREAL--(BUSINESS WIRE)--TOMAGOLD CORPORATION (TSXV: LOT; OTCPK: TOGOF) ("TomaGold†or the "Company†) announces that it has entered into an amendment (the "Amendment†) to the mineral property option agreement dated August 11, 2023 (the "Agreement†) with SOQUEM Inc. ("SOQUEM†). The Agreement and the Amendment relate to the David, Radar, Dufault, Williams, Brosman, McKenzie, and Bruneau properties. TomaGold and SOQUEM have agreed to amend the Agreement as follows: The anniversary date for Year. ...

Core Insights - The animated musical "David" by Angel is experiencing strong early domestic pre-sales, nearing $6 million, surpassing previous releases [1][2] - The film is set for a broad international release across 43 markets, reflecting high exhibitor confidence and a universal story theme [2][3] Company Overview - Angel (NYSE: ANGX) is a media and technology company supported by 1.6 million grassroots Angel Guild members who advocate for values-driven storytelling [1][9] - The company has a history of successful releases, including "Sound of Freedom," which grossed over $250 million globally [9] Film Details - "David" features a narrative centered on courage, faith, and hope, following the biblical story of David and Goliath [5] - The film is directed by Phil Cunningham and Brent Dawes, with music composed by Joseph Trapanese [6] Release Schedule - The U.S. release is scheduled for December 19, 2025, with international markets including Australia, New Zealand, and several Latin American countries following shortly after [3][7][11] Market Reception - Exhibitors express confidence in the film's potential, citing Angel's track record of delivering inspiring and high-quality films [4] - The film's themes resonate universally, appealing to diverse audiences across different regions [2][4] Upcoming Projects - Angel's future slate includes various genres, such as "I Was A Stranger," "Solo Mio," and "Young Washington," indicating a commitment to diverse storytelling [8]

Core Insights - Tempus AI's third-quarter 2025 results indicate a significant growth in its Insights and Data & Services business, which is becoming a high-margin revenue stream beyond traditional genomic testing [1][8] - Data and Services revenues reached $81.3 million, reflecting a 26.1% year-over-year increase, primarily driven by Insights (data licensing) [1][8] Business Performance - Insights bookings amounted to $150 million, showcasing a 37.6% year-over-year revenue growth, supported by a substantial foundation model deal signed earlier this year [2] - The company is effectively monetizing its extensive multimodal dataset, which includes genomic, clinical, imaging, and digital pathology information, alongside AI-powered insights and algorithms [2] Strategic Developments - Tempus enhanced its data and AI capabilities through the acquisition of Paige, a leader in digital pathology, which improves its dataset and technical expertise [3] - The collaboration with Northwestern Medicine has been expanded to integrate David, Tempus' generative AI clinical co-pilot, into the EHR platform, aiming to streamline clinical workflows [3] - Tempus Next has broadened its focus into breast cancer, providing real-time insights to assist clinicians in closing guideline-based care gaps [3] Market Position - Tempus is transitioning from a diagnostics-focused company to a differentiated data-driven precision medicine platform, with increasing potential for recurring revenue [4] - Over the past year, Tempus shares have increased by 10%, outperforming the industry, which saw a 4.1% decline [7] Valuation Metrics - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 8.18X, compared to the industry average of 5.81X, indicating a relatively expensive valuation [9]

Group 1 - Tempus AI Inc. is considered one of the least favorable AI stocks to invest in according to financial media [1] - An expanded collaboration between Northwestern Medicine and Tempus AI was announced, marking Northwestern Medicine as the first health system to integrate Tempus' generative AI-enabled clinical assistant, David, into its electronic health record (EHR) platform [1][2] - The partnership aims to enhance patient care by utilizing data and AI, building on a decade-long collaboration [2] Group 2 - The integration of David will provide Northwestern Medicine's clinical teams with real-time AI-enabled insights directly within the EHR [2][3] - By adopting Tempus' AI infrastructure, Northwestern Medicine will support its AI applications with a multimodal patient record, facilitating the co-development and real-time monitoring of new AI algorithms [3] - Clinical teams will be able to perform various functions, including building custom AI agents, querying patient data using natural language, and automating pre-appointment preparations with AI-generated summaries [3] Group 3 - Tempus AI Inc. specializes in healthcare technology, offering next-gen sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other pathology testing [4] - While there is potential for investment in Tempus AI, other AI stocks are viewed as having greater upside potential and lower downside risk [5]

Financial Data and Key Metrics Changes - The company reported total organic net sales down 3.5% in Q1, with an estimated 2.6% decline excluding the impact of the Hebrew National manufacturing disruption [26][28] - Adjusted operating margin declined 244 basis points year-over-year to 14.2% due to increased cost of goods sold inflation and higher merchandising investments [30][32] - Adjusted EPS was $0.53, down from $0.66 a year ago, primarily due to lower adjusted operating profit and unfavorable foreign exchange rates [32] Business Line Data and Key Metrics Changes - Grocery and Snacks segment delivered organic net sales of approximately $1.2 billion, a decline of 1.9% year-over-year, primarily from lower volumes [26] - Refrigerated and Frozen segment net sales were approximately $1.1 billion, down 5.7% from the prior year, significantly impacted by the Hebrew National disruption [27] - The International segment saw a 3% increase in organic net sales, driven by strong performance in global exports [28] Market Data and Key Metrics Changes - The company maintained a strong share performance, with approximately 71% of the portfolio holding or gaining volume share, outperforming peers [11][12] - In the frozen and snack domains, 93% of brands held or gained volume share during the quarter, indicating effective consumer engagement strategies [12][19] - The overall promotional environment remains rational, with Conagra operating with lower promotional volume compared to peers [13][14] Company Strategy and Development Direction - The company is focused on a value over volume strategy, particularly in foodservice, to sustain margins at pre-COVID levels [6][20] - Active portfolio reshaping initiatives were resumed, including the acquisition of Fatty Smoked Meat Sticks and divestiture of the Indian joint venture [7][23] - The company aims to achieve $1 billion in cost savings by the end of fiscal 2025 through productivity initiatives [6][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving fiscal 2025 goals despite challenges in the consumer environment [5][24] - The company anticipates sequential volume recovery each quarter and expects adjusted operating margin improvement in the second half of the fiscal year [35] - Inflationary pressures are expected to be around 3.2% for total cost of goods sold, with specific increases in proteins and sweeteners [36] Other Important Information - The company generated $269 million in net cash flows from operating activities in Q1, with capital expenditures of $133 million and dividends paid of $167 million [33][34] - Net leverage at the end of the quarter was 3.6 times, with a target of approximately 3.2 times by year-end [34] Q&A Session Summary Question: What were the impacts of the Hebrew National disruption on sales? - The disruption resulted in a 47% decline in revenue for the Hebrew National brand, equating to a 60 basis point reduction in total volume and a 90 basis point reduction in total organic net sales [7][8] Question: How is the company addressing inflationary pressures? - The company expects inflation of approximately 3.2% for total cost of goods sold, with specific pressures in proteins and sweeteners, but does not anticipate material impacts on margins or adjusted EPS from recent M&A transactions [36][37]